Gynecologic cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (Borderline Ovarian Tumors)

International Journal of Gynecological Cancer

Volumn 24, Issue 9, 2014, Pages S5-S8

  Harter, Philipp ^a   Gershenson, David ^b   Lhomme, Catherine ^c   Lecuru, Fabrice ^d   Ledermann, Jonathan ^e   Provencher, Diane M ^f   Mezzanzanica, Delia ^g   Quinn, Michael ^h   Maenpaa, Johanna ⁱ   Kim, Jae Weon ^j   Mahner, Sven ^k   Hilpert, Felix ^l   Baumann, Klaus ^m   Pfisterer, Jacobus ⁿ   Du Bois, Andreas ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

^b MDAndersen Cancer Center   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f NOTRE DAME HOSPITAL   (Canada)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h ANZGOG   (Australia)

ⁱ TAMPERE UNIVERSITY HOSPITAL   (Finland)

^j Seoul National University   (South Korea)

^k UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^l UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^m UKGM   (Germany)

ⁿ Gynecologic Oncology Center Kiel   (Germany)

more..

Author keywords

BOT; GCIG; Gynecologic Cancer InterGroup; Ovarian tumor of low malignant potential

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER ADJUVANT THERAPY; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CARCINOGENESIS; CONSENSUS; FEMALE; FOLLOW UP; HUMAN; MOLECULAR BIOLOGY; MULTICENTER STUDY (TOPIC); OVARY TUMOR; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); TUMOR DIAGNOSIS; CLASSIFICATION; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; OVARIAN NEOPLASMS; PATHOLOGY; PRACTICE GUIDELINE;

COMBINED MODALITY THERAPY; CONSENSUS; FEMALE; HUMANS; MEDICAL ONCOLOGY; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84988719515     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000282     Document Type: Review

References (22)

1. Acs G. Serous and mucinous borderline (low malignant potential) tumors of the ovary. Am J Clin Pathol. 2005;123:S13-S57.
2. Taylor HC Jr. Malignant and semi-malignant tumors of the ovary. Surg Gynecol Obstset. 1929;48:204-230.
3. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press, 2003.
4. Skirnisdottir I, Garmo H, Wilander E, et al. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008;123:1897-1901.
5. Coumbos A, Sehouli J, Chekerov R, et al. Clinical management of borderline tumours of the ovary: results of a multicentre survey of 323 clinics in Germany. Br J Cancer. 2009;100:1731-1738.
6. Baker P, Oliva E. A practical approach to intraoperative consultation in gynecological pathology. Int J Gynecol Pathol. 2008;27:353-365.
7. Du Bois A, Ewald-Riegler N, du Bois O, et al. Borderline tumors of the ovary-a systematic review [in German]. Geburtsh Frauenheilk. 2009;69:807-833.
8. du Bois A, Ewald-Riegler N, de Gregorio N, et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Study Group. Eur J Cancer. 2013;49:1905-1914.
9. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis. Cancer. 1988;62:2212-2222.
10. Song T, Lee YY, Choi CH, et al. Histologic distribution of borderline ovarian tumors worldwide: a systematic review. J Gynecol Oncol. 2013;24:44-51.
11. Hart WR. Borderline epithelial tumors of the ovary. Mod Pathol. 2005;18(suppl 2):S33-S50.
12. Burks RT, Sherman ME, Kurman RJ. Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am JSurg Pathol. 1996;20:1319-1330.
13. Buttin BM, Herzog TJ, Powell MA, et al. Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol. 2002;99:11-17.
14. Morice P, Uzan C, Fauvet R, et al. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. Lancet Oncol. 2012;13:e103-e115.
15. Kane A, Uzan C, Rey A, et al. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants. Oncologist. 2009;14:591-600.
16. Yokoyama Y, Moriya T, Takano T, et al. Clinical outcome and risk factors for recurrence in borderline ovarian tumours. Br J Cancer. 2006;94:1586-1591.
17. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene. 2005;24:1053-1065.
18. Odegaard E, Staff AC, Langebrekke A, et al. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy. Acta Obstet Gynecol Scand. 2007;86:620-626.
19. Longacre TA, McKenney JK, Tazelaar HD, et al. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. Am J Surg Pathol. 2005;29: 707-723.
20. Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009;114:48-52.
21. Darai E, Fauvet R, Uzan C, et al. Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options. Hum Reprod Update. 2013;19:151-166.
22. Cadron I, Leunen K, Van Gorp T, et al. Management of borderline ovarian neoplasms. J Clin Oncol. 2007;25:2928-2937.